Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
$10.30
$9.72
$18.20
$450MN/A2.07 million shs40,482 shs
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$10.70
$10.70
$3.95
$11.35
$292.42M2.38327,575 shs54 shs
OncoCyte Co. stock logo
OCX
OncoCyte
$2.89
+0.7%
$2.83
$2.08
$5.88
$23.91M0.844,613 shs6,088 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
0.00%0.00%0.00%0.00%0.00%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00%0.00%0.00%0.00%0.00%
OncoCyte Co. stock logo
OCX
OncoCyte
+0.70%+3.26%-0.35%-5.90%-46.21%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/AN/AN/AN/A
OncoCyte Co. stock logo
OCX
OncoCyte
1.8175 of 5 stars
3.32.00.00.02.82.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/A
OncoCyte Co. stock logo
OCX
OncoCyte
2.50
Moderate Buy$4.0640.57% Upside

Current Analyst Ratings

Latest FRX, OCX, HBP, and MDG1 Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
OncoCyte Co. stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$3.60 ➝ $4.25
4/17/2024
OncoCyte Co. stock logo
OCX
OncoCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$4.00
4/15/2024
OncoCyte Co. stock logo
OCX
OncoCyte
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$5.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/A$0.56 per shareN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$937.80M0.31$1.97 per share5.43$3.40 per share3.15
OncoCyte Co. stock logo
OCX
OncoCyte
$1.50M15.91N/AN/A$2.48 per share1.17

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
-$7.92MN/A0.00N/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$48.50M$1.776.05N/A5.17%66.00%15.67%N/A
OncoCyte Co. stock logo
OCX
OncoCyte
-$27.78MN/A0.00N/A-1,890.62%-96.30%-41.12%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/A
OncoCyte Co. stock logo
OCX
OncoCyte
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
0.37
0.37
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.75
2.05
0.95
OncoCyte Co. stock logo
OCX
OncoCyte
N/A
1.49
1.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
54.10%
OncoCyte Co. stock logo
OCX
OncoCyte
55.35%

Insider Ownership

CompanyInsider Ownership
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
10.95%
OncoCyte Co. stock logo
OCX
OncoCyte
1.94%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A37.50 millionN/ANot Optionable
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
1,10027.33 million24.34 millionOptionable
OncoCyte Co. stock logo
OCX
OncoCyte
758.27 million8.11 millionNo Data

FRX, OCX, HBP, and MDG1 Headlines

SourceHeadline
PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics MarketplacePRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
finance.yahoo.com - May 7 at 11:27 AM
3 Penny Stocks That Insiders Are Buying (OCX)3 Penny Stocks That Insiders Are Buying (OCX)
insidertrades.com - May 7 at 9:54 AM
OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.comOncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com
americanbankingnews.com - May 6 at 2:44 AM
Strong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial EfficiencyStrong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiency
markets.businessinsider.com - April 24 at 6:06 PM
Buffett Grabs More of This Stock, Plus Other Notable Insider BuyingBuffett Grabs More of This Stock, Plus Other Notable Insider Buying
msn.com - April 22 at 12:51 AM
OncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in StockOncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in Stock
insidertrades.com - April 16 at 4:46 AM
OncoCyte Corporation (OCX) Q4 2023 Earnings Call TranscriptOncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript
seekingalpha.com - April 13 at 10:47 PM
Q4 2023 OncoCyte Corp Earnings CallQ4 2023 OncoCyte Corp Earnings Call
finance.yahoo.com - April 13 at 1:38 AM
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 12 at 12:00 PM
Top 3 Health Care Stocks That May Collapse In Q2Top 3 Health Care Stocks That May Collapse In Q2
msn.com - April 12 at 10:36 AM
OncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayOncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
finanznachrichten.de - April 12 at 10:10 AM
S&P Futures Tick Lower as Investors Digest Big Bank EarningsS&P Futures Tick Lower as Investors Digest Big Bank Earnings
msn.com - April 12 at 10:10 AM
S&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank EarningsS&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank Earnings
msn.com - April 12 at 7:32 AM
Oncocyte announces $15.8 mln private placement of securitiesOncocyte announces $15.8 mln private placement of securities
msn.com - April 12 at 7:32 AM
ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTSONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS
prismmediawire.com - April 12 at 6:00 AM
Oncocyte Reports Full Year 2023 Financial ResultsOncocyte Reports Full Year 2023 Financial Results
globenewswire.com - April 12 at 6:00 AM
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
prismmediawire.com - April 11 at 9:48 PM
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
globenewswire.com - April 11 at 9:46 PM
Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayOncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
globenewswire.com - April 11 at 5:30 PM
Heres what Wall Street expects from Oncocytes earningsHere's what Wall Street expects from Oncocyte's earnings
markets.businessinsider.com - April 11 at 12:51 PM
ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS 
prismmediawire.com - April 9 at 4:05 PM
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial ResultsOncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
globenewswire.com - April 9 at 4:05 PM
NeuroBo stock jumps 14% on weight-loss drug updateNeuroBo stock jumps 14% on weight-loss drug update
msn.com - February 29 at 10:17 AM
OncoCyte Stock (NASDAQ:OCX), Short Interest ReportOncoCyte Stock (NASDAQ:OCX), Short Interest Report
benzinga.com - February 24 at 8:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Forest Road Acquisition logo

Forest Road Acquisition

NYSE:FRX
Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.
Huttig Building Products logo

Huttig Building Products

NASDAQ:HBP
Huttig Building Products, Inc., together with its subsidiaries, distributes millwork, building materials, and wood products for new residential construction, in-home improvement, remodeling, and repair works in the United States. The company offers various millwork products, including exterior and interior doors, pre-hung and factory finished door units, windows, patio doors, mouldings, frames, stair parts, and columns under the Therma-Tru, Masonite, Woodgrain, HB&G, Simpson Door, Final Frame, BrasPine, Arauco, Windsor Windows, and Rogue Valley Door brands. It also provides general building products, such as fasteners and connectors, roofing, siding, insulation, flashing, housewrap, decking, railings, and other miscellaneous building products under the Huttig-Grip, Louisiana-Pacific, Simpson Strong-Tie, TimberTech, AZEK, RDI, GAF Roofing, Maibec, Knauf, GCP Technologies, Fiberon, Alpha Protech, MFM, Lomanco, and Fortifiber brands. In addition, the company offers wood products comprising engineered wood products used in floor systems, wood panels, and lumber; and value-added services, such as floor system take-offs, cut-to-length packages and just-in-time, and cross-dock delivery under the Louisiana-Pacific and Rosboro brands. It markets and sells its products through a network of 25 wholesale distribution centers serving approximately 41 states to building materials dealers, national buying groups, home centers, and industrial users comprising makers of manufactured homes. Huttig Building Products, Inc. was founded in 1865 and is headquartered in St. Louis, Missouri.
OncoCyte logo

OncoCyte

NASDAQ:OCX
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.